EP1203095A2 - Recherche systematique de modulateurs de synthase d'oxyde nitrique - Google Patents

Recherche systematique de modulateurs de synthase d'oxyde nitrique

Info

Publication number
EP1203095A2
EP1203095A2 EP00948183A EP00948183A EP1203095A2 EP 1203095 A2 EP1203095 A2 EP 1203095A2 EP 00948183 A EP00948183 A EP 00948183A EP 00948183 A EP00948183 A EP 00948183A EP 1203095 A2 EP1203095 A2 EP 1203095A2
Authority
EP
European Patent Office
Prior art keywords
nos
modulator
human
coding sequence
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00948183A
Other languages
German (de)
English (en)
Inventor
Ian G. Wolfson Inst. for Biolog. Res. CHARLES
Weiming Wolfson Inst. for Biomedic. Res. XU
Lizhi Wolfson Inst. for Biomedic. Res. LIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918075.4A external-priority patent/GB9918075D0/en
Priority claimed from GB0016174A external-priority patent/GB0016174D0/en
Application filed by University College London filed Critical University College London
Publication of EP1203095A2 publication Critical patent/EP1203095A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • This invention relates to methods for identifying modulators of nitric oxide synthases.
  • Modulators of nitric oxide synthase activity can be used in the treatment of conditions in which the abnormal metabolism of nitric oxide is implicated.
  • NOS nitric oxide synthase
  • a good source of NOS is therefore required and ideally screening procedures for identifying inhibitors of NOS should involve a high through-put cell-based screen (HTS) against the human isoforms.
  • HTS high through-put cell-based screen
  • cell lines which are capable of producing NO in a dose- and time-dependent manner by treatment of the cells with ecdysone or an analog thereof or tetracycline or an analog thereof.
  • These cell lines thus provide sources of human iNOS, nNOS and eNOS that can be used in high through-put cell based screens for the identification of substances which can modulate the activity of those enzymes.
  • Modulators of activity of NOS enzymes are substances that can either activate or inhibit the activity of those enzymes.
  • a method for identifying a modulator of NOS activity comprising: (i) providing a polynucleotide construct which comprises:
  • a promoter operably linked to a coding sequence wherein the promoter is responsive to ecdysone or an analog thereof and the coding sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof; or (b) a promoter operably linked to one or more tetracycline operator site sequences and a coding sequence in that order, wherein the coding sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof; (ii) contacting a test substance with the construct under conditions that would permit the expression and activity of the NOS encoded by the coding sequence in the absence of the test substance; and (iii) dete ⁇ nining thereby whether the said substance modulates NOS activity.
  • the invention also provides: - a modulator of NOS activity identified by a method of the invention;
  • a modulator of the invention which is an inhibitor of NOS activity for use in a method of prophylaxis or treatment of the human or animal body by therapy; use of a modulator of the invention which is an inhibitor of NOS activity for the manufacture of a medicament for use in the prophylaxis or treatment of a clinical condition associated with excessive NO production;
  • composition comprising a modulator of the invention which is an inhibitor of NOS activity and a pharmaceutically acceptable carrier or diluent;
  • a method of preventing or treating a clinical condition in a host associated with excessive NO production comprises administering to the host a therapeutically effective amount of a modulator of the invention which is an inhibitor of NOS activity;
  • modulator of the invention which is an activator of NOS activity for use in a method of prophylaxis or treatment of the human or animal body by therapy;
  • a modulator of the invention which is an activator of NOS activity for the manufacture of a medicament for use in the treatment of a clinical condition associated with deficient NO production;
  • a pharmaceutical composition comprising a modulator of the invention which is an activator of NOS activity and a pharmaceutically acceptable carrier or diluent; - a method of preventing or treating a host suffering from a clinical condition in a host associated with deficient NO production which method comprises administering to the host a therapeutically effective amount of a modulator of the invention which is an activator of NOS activity; a polynucleotide construct comprising: (a) a promoter operably linked to a coding sequence, wherein the promoter is responsive to ecdysone or an analog thereof and the coding sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof; or (b) a promoter operably linked to one or more tetracycline operator site sequences and a coding sequence in that order, wherein the coding sequence encodes a nitric oxide synthase (NOS) or a functional variant thereof;
  • Figure 1(a) shows the plasmid map for pIND-hiNOS-f (human iNOS);
  • Figure 1 (b) shows the plasmid map for pLND-hnNOS-f (human nNOS);
  • Figure 1 (c) shows the plasmid map for p-L D-heNOS-f (human eNOS).
  • Figure 1(d) shows the plasmid map of pTet-hiNOS-f (human iNOS).
  • FIG. 2(a) shows generation of NO by EcR293 clone 11, following treatment with muristerone A.
  • EcR293 clone 1 1 cells were grown with varying concentrations of muristerone A and at different time intervals supernatants were taken and the Griess reaction was used to measure the nitrite concentration.
  • Figure 2(b) shows
  • Northern and Western blots of carried out on extracts from cells treated with either 1 ⁇ M or lO ⁇ M muristerone A. Extracts were also taken from cells grown in the absence of muristerone A.
  • Northern blots filters were probed with a human iNOS cDNA and hybridisation with human ⁇ -actin was used as a loading control.
  • Western blots filters were probed with a polyclonal antibody raised against the 7
  • Figure 3 shows generation of NO in a panel of cell lines transfected with pTet-hiNOS-f. Cells were treated with 1 ⁇ g/ml tetracycline for 24h and NOS activity was assessed by assaying for accumulated nitrite using the Griess reaction.
  • Figure 4 shows the results of an assay using two inhibitors of iNOS with EcR293 clone 1 1 cells. Bars 7 and 8 show control experiments; absence of muristerone A (MuA) or addition 5 ⁇ M muristerone A (MuA) respectively. Bars 1 to 6 show addition of 5 ⁇ M muristerone A and serial dilutions of L- ⁇ N-iminoethyl-L- ornithine (L-NIO) or 2-amino-5, 6-dihydro-6-methyl-4H-l, 3 thiazine hydrochloride (AMT).
  • L-NIO L- ⁇ N-iminoethyl-L- ornithine
  • AMT 2-amino-5, 6-dihydro-6-methyl-4H-l
  • Figure 5 shows the results of an assay using two inhibitors of iNOS with Tex293 clone 22 cells. Bars 1 and 2 show control experiments; absence of tetracycline (Tet) or addition of 0.025 ⁇ g/ml tetracycline (Tet) respectively. Bars 3 to 5 show addition of 0.025 ⁇ g/ml Tet and 20 ⁇ M L-NIO, 80 ⁇ M 1-NIO or 20 ⁇ M 1400W respectively.
  • Steroid hormones are small hydrophobic molecules that can diffuse through the plasma membrane of cells where they can bind reversibly to specific steroid- hormone-receptor proteins in the cytoplasm or nucleus.
  • the binding of hormone activates the receptor, enabling it to bind with high affinity to specific DNA sequences that act as trans criptional enhancers. This binding increases the level of transcription from certain nearby genes.
  • a pulse of the insect steroid hormone ecdysone triggers metamorphosis in
  • Drosophila melanogaster showing effects such as chromosomal puffing within minutes of hormone addition.
  • Mediating this response is the functional ecdysone receptor, which is a heterodimer of the ecdysone receptor (EcR) and the product of the ultraspiracle gene (USP).
  • EcR ecdysone receptor
  • USP ultraspiracle gene
  • Insect hormone responsiveness can be recreated in cultured mammalian cells by cotransfection of a cell with a functional ecdysone receptor (a heterodimer of EcR and USP) and an ecdysone responsive construct and treatment of the cell with ecdysone or an analog thereof.
  • a tetracycline responsive system can be created in cultured mammalian cells by cotransfection of a cell with a plasmid encoding a tetracycline repressor protein
  • tetR tetracycline responsive element linked to a promoter.
  • the promoter sequence is used to drive heterologous gene expression.
  • the tetracycline responsive element comprises particular DNA sequences called tetracycline operator sites, which can bind a homodimer of tetR. If those sequences are positioned between a promoter and a coding sequence in a construct, the presence of tetR bound to a tetracycline operator site will prevent the promoter driving expression of the coding sequence.
  • tetracycline when added to cells the tetracycline binds to tetR homodimers leading to a conformational change in tetR, such that it is unable to bind a tetracycline operator site.
  • the tetR: tetracycline complex dissociates from the Tet operator site and allows the promoter to drive expression of the coding sequence.
  • the invention provides polynucleotide constructs which are responsive to ecdysone or an analog thereof.
  • the invention also provides polynucleotide constructs which are responsive to tetracycline or an analog thereof.
  • the ecdysonse responsive constructs comprise a promoter operably linked to a coding sequence, wherein the promoter is responsive to ecdysone or an analog thereof and the coding sequence codes for a NOS or a functional variant or fragment thereof.
  • the tetracycline responsive constructs comprise a promoter operably linked to one or more teracycline operator site sequences and a coding sequence in that order, wherein the coding sequence codes for a NOS or a functional variant or fragment thereof.
  • the constructs may comprise DNA or RNA. They may also include within them synthetic or modified nucleotides. A number of different types of modification to polynucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule.
  • the constructs described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or lifespan of constructs of the invention. Constructs of the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art.
  • operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
  • a regulatory sequence such as a promoter
  • "operably linked" to a coding sequence is positioned in such away that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence.
  • a promoter for use in an ecdysone-reponsive construct of the invention may be any promoter which can drive the transcription of a coding sequence to which it is operably linked in the presence of the steroid hormone ecdysone or an analog thereof.
  • the promoter may be a naturally occurring promoter from a Drosophila melanogaster or other insect ecdysone-responsive gene.
  • the promoter may be a non-naturally occuring promoter.
  • a non-naturally occuring promoter may be used which comprises a minimal promoter and an ecdysone-responsive element (EcRE).
  • An EcRE is a nucleotide sequence to which a functional ecdysone receptor can bind in the presence of ecdysone.
  • Suitable minimal promoters include the minimal heat shock promoter.
  • An ecdysone-responsive promoter may comprise more than one EcRE, for example 2 to 10 elements or more preferably 4 to 6 elements.
  • the sequence of an EcRE will depend on the exact functional ecdysone receptor used. If a modified functional ecdysone receptor is used (see below) it may be appropriate to use a modified EcRE (see No et al., Proc. Natl. Acad. Sci. USA, 93: 3346-3351). The EcRE(s) and minimal promoter sequences do not have to be immediately adjacent.
  • EcREs function as transcriptional enhancers, they can be placed some distance upstream, for example from 1, 10 or 25 nucleotides to 30, 40, 50, 100, 500 or 1 OOOkb upstream of a minimal promoter. EcREs could even be placed further than lkb upstream of a minimal promoter. Generally, if multiple copes of an EcRE are used the mutiple copies will be arranged in an array, one after the other.
  • Constructs of the invention may be responsive to ecdysone [(2 ⁇ , 3 ⁇ , 5 ⁇ , 22R)- 2,3,14,22,25-pentahydroxycholest-7-en-6-one] or an analog thereof.
  • Suitable analogs of ecdysone for use in the invention include muristerone A [2 ⁇ , 3 ⁇ ,5 ⁇ , 1 l ⁇ ,
  • a promoter for use in an tetracycline-reponsive construct of the invention may be any promoter which can drive the transcription of a coding sequence to which it is operably linked in the presence of the antibiotic tetracycline or an analog thereof.
  • promoter will depend on the host cell to be used for expression of the coding sequence. Typically, expression in mammalian cells, for example human cells will be required and thus a mammlian promoter will be preferred. Mammalian promoters, such as ⁇ -actin promoters, may be used. Tissue- specific promoters may be used.
  • Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, adenovirus, HSV promoters (such as the HSV IE promoters), or HPV promoters, particularly the HPV upstream regulatory region (URR).
  • Viral promoters are readily available in the art. Constitutive promoters, for example the CMV promoter, are preferred.
  • Tetracycline-responsive constructs comprise one or more tetracycline operator site (TetO 2 ) sequences, situated between the promoter and coding sequence. For example, two, three, four or even up to ten TetO 2 sequences may be used.
  • TetO 2 tetracycline operator site
  • TetO 2 site typically, if more than one TetO 2 site is used those sites will be arranged in the form of an array. However, other intervening nucleotide sequences may be situated between individual TetO 2 sites. For example one, two, three, four, five, up to ten or up to 15 nucleotides may intervene between any two TetO 2 sites.
  • the TetO 2 sequence is 5'-TCCCTATCAGTGATAGAGA-3' (Hillen and
  • the TetO 2 sequence or a functional variant thereof is capable of being bound by a homodimer of tetR or a functional variant thereof.
  • a functional variant of the TetO 2 sequence is a sequence which is similar to that of the TetO 2 sequence and which remains capable of binding a homodimer of tetR or a functional variant thereof.
  • the binding affinity of tetR for a functional variant of the TetO 2 sequence may be substantially the same as that of tetR for the TetO 2 sequence.
  • tetR may have a binding affinity for a functional variant of the TetO 2 sequence which is greater or less than that of tetR for the TetO 2 sequence.
  • a functional variant of TetO 2 typically comprises a sequence substantially similar to that of the TetO 2 sequence.
  • a functional variant of TetO 2 will generally have at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to the TetO 2 sequence, calculated over the full length of those sequences.
  • a functional variant of the TetO 2 sequence may be a modified version of that sequence obtained by, for example, nucleotide substitution or deletion. Up to 1, up to 2, up to 3, up to 4, up to 5, up to 6 or more nucleotide substitutions or deletions or combinations thereof may be made to the TetO 2 sequence to produce a functional variant of that sequence.
  • Constructs of the invention may be responsive to the antibiotic tetracycline or an analog thereof. Tetracycline binds to tetR homodimers, such that the tetR:tetracylcine complex dissociates from the TetO 2 sequence.
  • the association constant of tetracycline to tetR is 3 x 10 9 M "1 .
  • Preferred analogs of tetracycline will have an association constant substantially similar to or greater than that of tetracycline for tetR. Suitable analogs of tetracycline include doxycycline.
  • Doxycycline exhibits similar dose response and induction characteristics with constructs of the invention, but has a longer half-life than tetracycline (48 hours vs. 24 hours respectively).
  • the coding sequence used in both ecdysone- and tetracycline-responsive contructs of the invention can be any sequence which encodes a NOS or a functional variant thereof.
  • the phrase "nitric oxide synthase" is intended to include all naturally occuring forms of iNOS, nNOS and eNOS as well as variants which retain NOS activity, for example variants produced by mutagenesis techniques.
  • the coding sequence encodes a NOS of marnrnlian origin for example rodent (including rat and mouse) or human.
  • the coding sequence encode the human iNOS (GenBank accession number: X73029, Coding sequence 226-3687), human nNOS (GenBank accession number: U 17327, Coding sequence 686-4990) or human eNOS (GenBank accession number: M95296, Coding sequence 21-3632) or a functional variant of any one of those enzymes.
  • a functional variant of a NOS is any polypeptide which demonstrates NOS activity, for example a fragment of a NOS.
  • a coding sequence which codes for a functional variant of a NOS may be, for example a fragment of a full length NOS coding sequence.
  • a fragment may be of any length, so long as the polypeptide for which it codes has NOS activity.
  • a functional variant of a NOS typically comprises a sequence substantially similar to that of the naturally occurring form of the relevant NOS sequence.
  • a functional variant of a NOS will generally have at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to the relevant NOS sequence, calculated over the full length of those sequences.
  • the coding sequence may be modified by nucleotide substitutions or deletions. For example up to 1, 2 or 3 to 10, 25, 50, 75 or 100 substitutions or deletions or combinations thereof may be made to produce a functional variant of a NOS.
  • a polynucleotide encoding a NOS may alternatively or additionally be modified by one or more insertions and/or deletions and/or by an extension at either or both ends.
  • the modified polynucleotide generally encodes for a polypeptide which has NOS activity. Degenerate substitutions may be made and/or substitutions may be made which would result in a conservative arnino acid substitution when the modified sequence is translated, for example as shown in the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.
  • Sequence identity may be calculated as follows.
  • the UWGCG Package provides the BESTFIT program which can be used to calculate identity (for example used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387- 395).
  • the PILEUP and BLAST algorithms can be used to calculate identity or line up sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol 215:403-10.
  • Software for performing BLAST analyses is publicly available through the National Centre for Biotechnology Information (http://www.ncbi.nlm.nih.gov/)
  • Both types of construct of the invention can be incorporated into a recombinant replicable vector.
  • the vector may be used to replicate the construct in a compatible host cell.
  • a vector may also provide for expression of the NOS coding sequence when the vector is harboured by an appropriate host cell.
  • the vectors may be for example, plasmid, virus or phage vectors provided with an origin of replication and optionally a regulator of the ecdysone-responsive promoter or promoter used in a tetracycline-responsive construct.
  • the vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene for selection in bacterial cells or a G418 or a zeocin resistance gene for selection in mammalian cells.
  • selectable marker genes for example an ampicillin resistance gene for selection in bacterial cells or a G418 or a zeocin resistance gene for selection in mammalian cells.
  • Vectors of the invention which incorporate an ecdysone-inducible construct, may be introduced into a suitable host cell by any appropriate transformation or transfection technique.
  • the host cell will permit the expression of the NOS coding sequence.
  • the cells may be chosen to be compatible with the said vector and may be for example bacterial, yeast, insect or mammalian cells.
  • NOS gene expression to be induced in the presence of ecdysone or an analog thereof a cell harbouring an ecdysone inducible construct must preferably also be capable of expressing a functional ecdysone receptor
  • the wild type Drosophila functional ecdysone receptor is a heterodimer of the ecdysone receptor (EcR) and the product of the ultraspiracle gene (USP)
  • EcR ecdysone receptor
  • USP ultraspiracle gene
  • cells of the invention may be capable of expressing EcR and USP.
  • EcR's natural heterodimeric partner USP with its mammlian homologue retinoid X receptor gives a heterodimer which can give more potent induction of an ecdysone responsive promoter.
  • cells of the invention may be capable of expressing EcR and RXR.
  • cells of the invention may be capable of expressing functional variants of either subunit of the heterodimer
  • Functional variants of EcR and USP/RXR are polypeptides which can heterodime ⁇ se with their partner and can, when heterodimerised, allow ecdysone- responsive dimerisation to occur. In some cases functional variants may bind to non- wild type EcREs. Examples of functional variants and modified EcREs are described in No et al. Proc. Natl. Acad. Sci. USA, 93: 3346-3351.
  • Preferred cells for use in the invention are human cells.
  • Particularly preferred cells are EcR293 cells (Invitrogen, San Diego, CA; Catalogue No: R650-07; EcR293 is a derivative of the human fetal kidney cell line HEK293 (ECACC accession number 85/20602)).
  • EcR293 cells are particularly suitable as they stably transformed with the vector pVgRXR. That vector is capable of expressing a functional variant of EcR, VgEcR, and RXR in mammalian cells and thus allows the expression of a functional ecdysone receptor.
  • Other suitable cell lines include EcR-CHO and EcR- 3T3 (Invitrogen, San Diego, CA; Cat. Nos: R660-07 and R680-07 respectively). Those two cell lines are stably transformed with the same vector, pVgRXR, as the EcR293 cell line.
  • Vectors of the invention which incorporate an tetracycline-inducible construct, may be introduced into a suitable host cell by any appropriate transformation or transfection technique.
  • the host cell will permit the expression of the NOS coding sequence in the presence of tetracycline or an analog thereof.
  • the cells may be chosen to be compatible with the said vector and may be for example bacterial, yeast, insect or mammalian cells.
  • NOS gene expression to be regulated such that expression does not occur in the absence of tetracycline, a cell harbouring a tetracycline-inducible construct must preferably also be capable of expressing the tetracycline repressor protein (tetR) or a functional variant thereof.
  • tetR tetracycline repressor protein
  • a functional variant of tetR is a polypeptide which is similar to tetR and which remains capable of binding, as a homodimer, the TetO 2 site or a functional variant thereof and tetracycline or an analog thereof.
  • the binding affinity of a functional variant sequence of tetR for the TetO 2 site or a functional variant thereof or tetracycline or an analog thereof may be substantially the same as the binding affinity of the tetR polypeptide for the TetO 2 site or a functional variant thereof or tetracycline or an analog thereof.
  • a functional variant sequence may have a binding affinity which may be greater or less than that of the tetR polypetide.
  • the TetR gene encodes a repressor protein of 207 amino acids with a calculated molecular weight of 23 kDa (Hillen and Berens, 1994, supra).
  • a functional variant of tetR typically comprises an amino acid sequence substantially similar to that of the tetR sequence.
  • a functional variant of a tetR will generally have at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to tetR, calculated over the full length of those sequences. The calculation of sequence identities is described above.
  • a functional variant of the tetR sequence may be a modified version of that sequence obtained by, for example, amino acid substitution or deletion. Up to 1, up to 10, up to 20, up to 50, up to 75, up to 100 or more amino acid substitutions or deletions or combinations thereof may be made to the tetR sequence to produce a functional variant of that sequence Substitutions are preferably made which result m a conservative ammo acid substitution, for example as shown in the Table above
  • Preferred cells for use in the invention are human cells Particularly preferred cells are T-REx cells (Invitrogen, San Diego, CA, Catalogue Nos R710-07, R712- 07, R714-07 and R716-07) T-Rex cells are particularly suitable as they stably transformed with the plasmid pcDNA6/TR which generates high level expression of the tetR polypeptide
  • T-REx cells are particularly suitable as they stably transformed with the plasmid pcDNA6/TR which generates high level expression of the tetR polypeptide
  • any cell line can be used which expresses tetR or a functional va ⁇ ant thereof
  • the principle behind the assays of the invention is to screen for compounds which modulate NOS activity
  • the assays can also be used to screen foi compounds which specifically modulate only one of the NOS isoforms
  • the invention provides a method for identifying a modulator of NOS activity compnsmg
  • a promoter operably linked to a coding sequence wherein the promoter is responsive to ecdysone or an analog thereof and the codmg sequence encodes a nit ⁇ c oxide synthase (NOS) or a functional va ⁇ ant theieof, or
  • a construct can be incorporated mto a vector and the resulting vector can be contacted with the test substance as desc ⁇ bed in the above method.
  • a construct of the invention or a vector incorporating a construct of the invention may be harboured by a cell and that cell may be contacted with the test substance.
  • any suitable assay format may be used for identifying a modulator of NOS activity.
  • the assay is, however, typically carried out in a single medium. Most preferably the assay is carried out in a single well of a plastics microtitre plate, so that high through-put screening for modulators of NOS activity may be carried out.
  • cells may be grown in the presence of the test substance and ecdysone or an analog thereof or tetracycline or an analog thereof depending on the construct used. Enzymatic action of NOS may be commenced by the addition of a test substance and ecdysone or an analog thereof or tetracycline or an analog thereof depending on the construct used. Enzymatic action of NOS may be commenced by the addition of a test substance and ecdysone or an analog thereof or tetracycline or an analog thereof depending on the construct used. Enzymatic action of NOS may be commenced by the addition of a test substance and ecdysone or an analog thereof or tetracycline or an analog thereof depending on the construct used. Enzymatic action of NOS may be commenced by the addition of a test substance and ecdysone or an analog thereof or tetracycline or an analog thereof depending on the construct used. Enzymatic action of NOS may be commenced by the addition of a test substance and e
  • NOS substrate for example L-arginine.
  • the activity of the NOS is then determined.
  • Known NOS modulators eg. the NOS inhibitor L-N 6 -( 1 -iminoethyl)lysine (L-NMMA) or the NOS activator tetrahydrobiopterin (BH 4 ) may be used as positive controls, in order to show that the expressed enzymes are indeed capable of modulation.
  • a test substance may be tested with any other known enzyme to exclude the possibility that the test substance is a general modulator of enzyme activity.
  • the reaction mixture will typically contain a suitable buffer, suitable cofactors and suitable cations as cofactors.
  • a suitable buffer includes any suitable biological buffer that can provide buffering capability at a pH conducive to the reaction requirements of NOS enzymes. All three enzymes require NADPH, FMN, FAD, BH 4 and calmodulin for activity. eNOS and nNOS also require calcium.
  • the assay may be carried out at any temperature at which a NOS, in the absence of any inhibitor, is active. Typically, however, the assay will be carried out in the range of from 25°C to 37°C.
  • Measures of the enzymatic activity of a NOS will be generally known to those skilled in the art, including equilibrium constants, reaction velocities of the appearance of reaction products or the consumption of reaction substrates, reaction kinetics, thermodynamics of reaction, spectrophotometric analysis of reaction products, detection of labelled reaction components, etc.
  • NOS activity can be measured in a number of ways (Methods in Enzymology 268, L Packer (Ed ) Academic Press, 1996) For example, NOS activity can be measured directly by conversion of radiolabelled argimne to citrulhne or indirectly by assaying for NO production Assays for NO include chemical assays and bioassays A typical assay for NO is descnbed m Green et al , 1982, Analysis of nitrate, nitrite and [ 15 N] nitrate m biological fluids, Anal Chem.
  • - cells harbou ⁇ ng a vector of the mvention are inoculated in a suitable growth medium into the wells of a plastics micro-titre plate and grown to semi-confluence or confluence,
  • - mu ⁇ stone A is added to a final concentration of 1-1 O ⁇ M or tetracycline is added to a final concentration of about 0 025 ⁇ g/ml along with the substance or pool of substances to be tested and the cells are incubated overnight, - lOO ⁇ l of the culture supernatant is mixed with lOO ⁇ l of G ⁇ ess reagent ( 1 1 mixture of 1% sulfamlamide in 5% H 3 P0 4 and 0 1% napthylethylenediamme dihydrochlonde in water) for 10 mm at room temperature and absorbance at 543nm is measured, and
  • Suitable test substances which can be tested in the above assays include combmatonal hbranes, defined chemical identities, peptide and peptide mimetics, ohgonucleotides and natural product hbranes, such as display hbranes (eg phage display hbranes) and antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimaeric antibodies and CDR-grafted antibodies) which are specific for NOS enzymes in general or specific for one of the NOS isoforms or mimics thereof.
  • display hbranes eg phage display hbranes
  • antibody products for example, monoclonal and polyclonal antibodies, single chain antibodies, chimaeric antibodies and CDR-grafted antibodies
  • test substances include analogs of arginine, aminoguanidine or analogues thereof, guanidine compounds, isothiourea, derivatives of L-N 6 -(l-iminoethyl)lysine (L-NMMA), 2-nitroaryl and 2-cyanoaryl compounds, ⁇ -(S-methylisothioureido)-L-norvaline and BH 4 , ie. analogs of known inhibitors and activators of NOS.
  • Test substances may be used in an initial screen of, for example, ten substances per reaction, and the substance of these batches which show inhibition or activation tested individually Test substances may be used at a concentration of from l ⁇ M to lOOO ⁇ M, preferably from l ⁇ M to lOO ⁇ M, more preferably from l ⁇ M to lO ⁇ M
  • a substance which inhibits or activates the activity of NOS may do so by binding the enzyme.
  • Such enzyme inhibition or activation may be reversible or i ⁇ eversible
  • An i ⁇ eversible inhibitor or activator dissociates very slowly from its target enzyme because it becomes very tightly bound to the enzyme, either covalently or non-covalently Reversible inhibition or activation, in contrast with i ⁇ eversible inhibition or activation, is characterised by a rapid dissociation of the enzyme- mhibitor/activator complex
  • the test substance may be a competitive inhibitor.
  • the enzyme can bind substrate (forming an enzyme-substrate complex) or inhibitor (enzyme-inhibitor complex) but not both. Many competitive inhibitors resemble the substrate and bind the active site of the enzyme. The substrate is therefore prevented from binding to the same active site.
  • a competitive inhibitor diminishes the rate of catalysis by reducing the proportion of enzyme molecules bound to a substrate.
  • the inhibitor may also be a non-competitive inhibitor.
  • non-competitive inhibition which is also reversible, the inhibitor and substrate can bind simultaneously to an enzyme molecule. This means that their binding sites do not overlap
  • a non-competitive inhibitor acts by decreasing the turnover number of an enzyme rather than by diminishing the proportion of enzyme molecules that are bound to substrate.
  • the inhibitor can also be a mixed inhibitor. Mixed inhibition occurs when an inhibitor both effects the binding of substrate and alters the turnover number of the enzyme.
  • a substance which inhibits the activity of NOS may also do so by binding to the substrate.
  • the substance may itself catalyse a reaction of the substrate, so that the substrate is not available to the enzyme.
  • the inhibitor may simply prevent the substrate binding to the enzyme.
  • a substance which is an activator may increase the affinity of the substrate for the enzyme or vice versa. If this is the case the proportion of enzyme molecules bound to substrate molecules is increased and the rate of catalysis will thus increase.
  • An activator may increase the affinity of a substrate for an enzyme by binding to the enzyme or substrate or both.
  • a modulator of NOS activity is one which produces a measurable reduction or increase in NOS activity in the assays described above.
  • Prefe ⁇ ed inhibitors are those which inhibit NOS activity by at least 10%, at least 20%, at least 30%, at least 40% at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% at a concentration of the inhibitor of l ⁇ g ml "1 , lO ⁇ g ml "1 , lOO ⁇ g ml "1 , 500 ⁇ g ml- ⁇ lmg ml "1 ' lOmg ml "1 , lOOmg mr 1 .
  • Prefe ⁇ ed activators are those which activate NOS activity by at least 10%, at least 25%. at least 50%, at least 100%, at least, 200%, at least 500% or at least
  • the percentage inhibition or activation represents the percentage decrease or increase in activity of NOS in a comparison of assays in the presence and absence of the test substance. Any combination of the above mentioned degrees of percentage inhibition or activation and concentration of inhibitor or activator may be used to define an inhibitor or activator of the invention, with greater inhibition or activation at lower concentrations being preferred.
  • Candidate substances which show activity in assays such as those described above can be tested in in vivo systems.
  • the modulation of eNOS and iNOS in situ in rat aortic rings can assessed by measuring the change in ring tension caused by candidate substances.
  • endothelium-denuded rings are typically exposed to LPS (0.1 ⁇ g ml from S. thphosa) in the presence of phenylephrine at approximately ED 90 for 6 h as described in Rees et al. (1990). During this time a progressive loss of tone usually occurs because of iNOS induction. Generally, cumulative concentration curves are then obtained for the candidate substances.
  • mice The inhibition or activation of eNOS and iNOS in vivo can also be assessed by the effects of inhibitors on blood pressure in mice.
  • one suitable method is as follows. Mice are anaesthetised briefly with isoflourane (2%). Cannula lines are implanted in a femoral vein, tunnelled subcutaneous ly to exit at the top of the back and connected to a swivel tether system for continuous monitoring of blood pressure and for candidate substance administration respectively. Following recovery from surgery, animals with mean blood pressures in the normal range (90- 1 10 mm Hg) are used to obtain cumulative concentration curves for candidate substances on blood pressure. It will be appreciated that other suitable assays may be used to determine whether a candidate substance shows modulation of NOS activity in vivo and that the above mentioned assays are by way of example.
  • candidate modulators may be tested in an animal model of target disease state.
  • Modulators of NOS activity can be used in the treatment of conditions in which the abnormal metabolism of nitric oxide is implicated.
  • the invention also provides use of a modulator of NOS activity for the manufacture of a medicament for use in the treatment of a clinical condition associated with abnormal NO production.
  • Modulators identified by a method of the invention which are inhibitors of NOS activity may be used to prevent, alleviate or treat this potentially fatal response.
  • Modulators of the invention which are inhibitors may also be used to treat other conditions in which over-production of NOS is implicated, for example ischaemia-reperfusion injury of the brain or heart, cancer, multiple sclerosis, lethal hypotension in severe inflammatory conditions such as septic shock or multi-organ failure, or local and systemic inflammatory disorders including arthritis, skin disorders, inflammatory cardiac disease or inflammatory bowel disease.
  • Over- production of NOS is also implicated in various neurological disorders including strokes, dementia, Parkinson's disease and Alzheimer's disease.
  • the condition of a patient suffering from one of the above mentioned conditions can therefore be improved by administration of a modulator of the invention which is an inhibitor of NOS activity.
  • a therapeutically effective amount of such a modulator may be given to a human patient in need thereof.
  • Deficient production is implicated in a number of clinical conditions including, for example, hyperlipidaemia, renal failure, hypertension, restenosis after angioplasty, atherosclerosis, complications of heart failure, schizophrenia and cancer.
  • Modulators of the invention which are activators of NOS activity may be used to prevent, alleviate or treat any one of those conditions.
  • the condition of a patient suffering from one of the above mentioned conditions can therefore be improved by administration of such a modulator.
  • a therapeutically effective amount of such a modulator may be given to a human patient in need thereof.
  • Modulators of NOS activity may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
  • the inhibitors may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques.
  • the modulators may also be administered as suppositories. A physician will be able to determine the required route of administration for each particular patient.
  • the formulation of a modulator for use in prophylaxis or treatment will depend upon factors such as the nature of the exact modulator, whether a pharmaceutical or veterinary use is intended, etc.
  • An modulator may be formulated for simultaneous, separate or sequential use.
  • a modulator of NOS activity is typically formulated for administration in the present invention with a pharmaceutically acceptable carrier or diluent.
  • the pharmaceutical carrier or diluent may be, for example, an isotonic solution.
  • solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g.
  • starches arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl py ⁇ olidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.
  • Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film coating processes.
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
  • Solutions for intravenous or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
  • a therapeutically effective amount of a modulator is administered to a patient.
  • the dose of modulator may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular patient.
  • a typical daily dose is from about 0.1 to 50 mg per kg, preferably from about 0. Img/kg to lOmg/kg of body weight, according to the activity of the specific inhibitor, the age, weight and conditions of the subject to be treated, the type and severity of the degeneration and the frequency and route of administration.
  • daily dosage levels are from 5 mg to 2 g.
  • the cells were then transfe ⁇ ed to three or four T-25 flasks (or equivalent) and placed in a humidified, 37 °C, 5% CO 2 incubator. It typically took 3-4 days for cell cultures to reach 80-90% confluency. Media were changed 2 times a week and cells subcultured at a ratio of 1 :3 to 1:4 when they reached 80-90% confluency. Cells were subcultured when approaching confluency to avoid the accumulation of floating and dead cells. Cells were frozen for storage in 95% FBS and 5% DMSO.
  • Cells could be maintained in non selection medium for 2-3 weeks without losing inducibility following muristerone A treatment.
  • Non-selection medium was used by choice, although selection medium worked equally well.
  • Cells were seeded at 1-2 x 10 5 /ml concentration for 12 well or 96 well plates. Semi-confluent or confluent plates or flasks were used for induction.
  • Figure 1(a) shows overnight induction in 12 well plates (3-30 hours) following the addition of different doses of muristerone A. Nitrate concentrations are measured using the Griess Reaction (see below).
  • Poly(A) + mRNA was isolated using a micro-fastrack mRNA purification kit (Invitrogen), separated by electrophoresis and transfe ⁇ ed onto Hybond N membrane
  • NOS activity assay Griess Reaction (Green et al., 1982, Analysis of nitrate, nitrite and [ 15 N] nitrate in biological fluids, Anal. Chem. 126, 131-138): NOS activity was determined for both intact cells and their lysates. For intact cells, lOO ⁇ l of the culture medium was mixed with lOO ⁇ l of Griess reagent (1 : 1 mixture of 1% sulfamlamide in 5% H 3 P0 4 and 0.1% naphthylethyethylenediamine dihydrochloride in water) for 10 min at room temperature and the absorbance at 543 nm was recorded. A serial dilution of sodium nitrite was used as a standard.
  • lOO ⁇ g of lysate was mixed with lOO ⁇ l reaction reagent from the NOS detect system (Stratagene NOS detect kit, Cat. No. 204500).
  • the kit measures the conversion of [ 14 C]arginine to [ 14 C] citrulline, and is specific for the NOS pathway.
  • Example 1 Generation of NOS transfected cell lines under the control of an ecdysone-responsive or a tetracycline-responsive promoter
  • Three plasmids were generated, each of which expressed one of the human NOS isoforms under the control of an ecdysone-responsive promoter.
  • An additional plasmid was constructed placing the iNOS cDNA under the control of a tetracycline- regulated promoter.
  • Coding sequence 226-3687 was cut from its original vector (Bluescript KS) using the restriction endonucleases, Kpnl and Spel and cloned into pIND (Invitrogen, San Diego, CA. Catalogue No: V705-20) which had been cut with Kpnl and Xbal. The resulting plasmid was sequenced to confirm that the cDNA had inserted in the co ⁇ ect orientation.
  • 5kb of the human nNOS cDNA (GenBank accession number: U17327, Coding sequence 686-4990) was cut from its original vector (Bluescript KS) using the restriction endonucleases, Xbal and Kpnl and cloned into pIND (Invitrogen, San Diego, CA, Catalogue No V705-20) which had been cut with Nhel and Kpnl.
  • the resulting plasmid was sequenced to confirm that the cDNA had inserted in the co ⁇ ect orientation.
  • the human iNOS cDNA (GenBank accession number: X73029, Coding sequence 226-3687) was cut from its original vector (Bluescript KS) using the restriction endonucleases, Kpnl and Spel and cloned into pcDNA4/TO (Invitrogen,
  • the pIND plasmid contains 5 modified EcREs called E/GREs which bind a modified functional ecdysone receptor. That modified functional ecdysone receptor can be expressed by another plasmid, pVgRXR (Invitrogen, San Diego, CA; Catalogue Number: V730-20). pVgRXR constitutively expresses a heterodimeric receptor comprising a modified ecdysone receptor (VgEcR) and RXR.
  • VgEcR modified ecdysone receptor
  • a cell transformed with pVgRXR and one of the three plasmids described above (I, ⁇ or III) will express NOS in the presence of ecdysone or an analog thereof. In the presence of ecdysone the functional ecdysone receptor binds to the E/GREs and transcription of the NOS cDNA is initiated.
  • the plasmid pIND-hiNOS-f was used to transfect a human fetal kidney cell line, EcR293 (Invitrogen, San Diego, CA; Catalogue No: R650-07), which is stably transformed with pVgRXR. Transfections were carried out using Superfect reagent (Qiagen) and transfectants were isolated following double selection on G418
  • cells were isolated which constitutively expressed the subunits of a functional ecdysone receptor, RXR/VgEcR and the human iNOS cDNA under the control of an ecdysone-inducible promoter.
  • the T-Rex system (Invitrogen, San Diego, CA, Catalogue No: K 1020-01) is a tetracycline-regulated mammalian expression system that uses regulatory elements from the E. coli Tn/0-encoded tetracycline resistance operon.
  • the pcDNA4/TO plasmid allows expression of a gene of interest under te control of the strong human cytomegalovirus immediate-early (CMV) promoter and two tetracycline operator 2
  • CMV human cytomegalovirus immediate-early
  • the pcDNA6/TR plasmid expresses high levels of the TetK gene under the control of the human CMV promoter.
  • a cell transformed with pcDNA6/TR and the plasmid described above (TV) will express NOS in the presence of tetracycline or an analog thereof.
  • tetracycline binds to tetR which undergoes a conformational change such that it dissociates from the TetO 2 sites. Expression of the iNOS gene is then induced, driven by the CMV promoter.
  • the plasmid pTet-hiNOS-f was used to transfect the cell line T-REx-293 ((Invitrogen, San Diego, CA; Catalogue No: R710-07).
  • the T-REx-293 cell line is a human embryonic kidney 293 cell line which has been transfected with the pcDNA6/TR plasmid and thus generates high level expression of the tetracycline repressor protein (TetR).
  • Transfections were carried out using conditions as described above for the muristerone A inducible constructs. Transfectants were isolated following selection on zeocin (200 ⁇ g/ml) for the human iNOS cDNA expressing plasmid and blasticidin (5 ⁇ g/ml) for the tetR expressing plasmid.
  • tetracycline repressor protein tetR
  • human iNOS cDNA tetracycline repressor protein
  • Example 2 Isolation and characterization of ecdysone-responsive and tetracycline-responsive human cell lines
  • a panel of 20 G418/zeocin-resistant clones were examined for their ability to generate NO. A total of 5 were identified that could be induced to produce NO at varing levels after treatment with lOO ⁇ M muristerone A for 24 hours. NOS activity was determined in both intact cells and in cell lysates. For intact cells, the Griess reaction was used to determine the concentration of NO in lOO ⁇ l of culture medium.
  • lOO ⁇ g of cell lysate was mixed with lOO ⁇ l reaction reagent from NOS detect system (Stratagene NOS detect kit, Cat. No.204500).
  • the kit measures the conversion of [ 14 C] arginine to [ 14 C] citrulline, and is specific for NOS.
  • transfectants were plated out on 12 well Falcon tissue culture plates at a cell density of 1 x 107ml and nitrite was measured by the Griess reaction.
  • Muristerone A (Invitrogen) was added at a final concentration of lOO ⁇ M to specific wells, and after induction for 24hr, lOO ⁇ l of culture supernatant was used to measure nitrite concentration using the Griess reagent. The results are reported as the average of assays run on triplicate wells. Well-to-well variation was less than 10%.
  • transfectants clone 11
  • clone 11 One of the transfectants, clone 11, was selected for further study.
  • Cells were grown with varying concentrations of muristerone A, and at different time intervals, supematants were taken and the Griess reaction was used to measure the nitrite concentration. The results are reported as the average of assays run in triplicate.
  • a panel of 4 tetracycline-regulated iNOS expressing cell lines were isolated, designated clone 1, clone 2, clone 5 and clone 22.
  • the iNOS transfectants were unable to express mRNA as the two Tet operator sites (Tet0 2 ) are occupied by the repressor protein effectively blocking transcription.
  • Tet0 2 Tet operator sites
  • tetracycline is added to the culture medium, it binds to the TetR protein and changes its conformation. The altered conformation of the repressor is unable to bind the operator sites, and consequently iNOS can be expressed.
  • Nitrite concentrations were determined using the Griess reaction (see figure 3).
  • Cells were seeded at l-2xl0 5 /ml concentration for 12 well or 96 well plates. Semi-confluent or confluent plates or flasks were used for induction with muristerone A (l-10 ⁇ M). To test iNOS inhibitors, the test compounds were dissolved in an appropriate solvent and added to the tissue culture plates at the same time as muristerone A. The cells were cultured overnight. lOO ⁇ l of cultured medium supernatant was mixed with lOO ⁇ l of Griess reagent (1:1 mixture of 1% sulfanilamide in 5% H 3 PO 4 and 0.1% naphthylethyethylenediamine dihydrochloride in water) for 10 min at room temperature and the absorbance at 543 nm was recorded.
  • muristerone A l-10 ⁇ M
  • Figure 4 shows the results of tests using 12 well plates for two iNOS inhibitors, L-NIO (N-iminoethyl-L-ornithine) and AMT hydrochloride (2-amino-5, 6-dihydro-6-methyl-4H-l, 3 thiazine hydrochloride).
  • L-NIO N-iminoethyl-L-ornithine
  • AMT hydrochloride 2-amino-5, 6-dihydro-6-methyl-4H-l, 3 thiazine hydrochloride
  • Example 4 Screening for inhibitors of human iNOS using the TEx-293 clone 22 cell line
  • Example 3 The same protocol was followed as for Example 3 above. Inhibition of NOS activity was determined by comparing nitrite concentration between the different treatments and controls.
  • Figure 3 shows the results of tests using 12 well plates for two iNOS inhibitors, L-NIO and 1400W.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant d'identifier un modulateur d'activité de la synthase d'oxyde nitrique, NOS, qui consiste à (i) fournir une construction polynucléotidique comprenant (a) un promoteur fonctionnellement lié à une séquence de codage, le promoteur réagissant à l'ecdysone ou analogue, et la séquence de codage codant une synthase d'oxyde nitrique (NOS) ou une variante fonctionnelle de celle-ci; ou (b) un promoteur fonctionnellement lié à au moins une séquence de site opérateur de tétracycline et une séquence de codage dans cet ordre, ladite séquence de codage codant une synthase d'oxyde nitrique (NOS) ou une variante fonctionnelle de celle-ci; (ii) mettre en contact une substance d'essai avec ladite construction dans des conditions qui permettraient l'expression et l'activité de NOS codée par la séquence de codage en l'absence de ladite substance; et (iii) déterminer ainsi si ladite substance module l'activité NOS. On peut utiliser des modulateurs d'activité de la synthase d'acide nitrique dans le traitement de conditions concernant le métabolisme anormal de l'oxyde nitrique.
EP00948183A 1999-07-30 2000-07-28 Recherche systematique de modulateurs de synthase d'oxyde nitrique Withdrawn EP1203095A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9918075.4A GB9918075D0 (en) 1999-07-30 1999-07-30 Screen for nitric oxide synthase modulators
GB9918075 1999-07-30
GB0016174 2000-06-30
GB0016174A GB0016174D0 (en) 2000-06-30 2000-06-30 Screen for nitric acid synthase modulators
PCT/GB2000/002926 WO2001009307A2 (fr) 1999-07-30 2000-07-28 Recherche systematique de modulateurs de synthase d'oxyde nitrique

Publications (1)

Publication Number Publication Date
EP1203095A2 true EP1203095A2 (fr) 2002-05-08

Family

ID=26244582

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00948183A Withdrawn EP1203095A2 (fr) 1999-07-30 2000-07-28 Recherche systematique de modulateurs de synthase d'oxyde nitrique

Country Status (3)

Country Link
EP (1) EP1203095A2 (fr)
AU (1) AU6174600A (fr)
WO (1) WO2001009307A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759836A (en) * 1995-03-27 1998-06-02 Hospital For Joint Diseases Osteoarthritis-associated inducable isoform of nitric oxide synthetase
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
EP0948619A1 (fr) * 1996-12-09 1999-10-13 Ariad Gene Therapeutics, Inc. Expression de proteines pour traiter l'asthme via l'activation, par ligand mediateur, de leurs genes de codage
HN1998000125A (es) * 1997-08-28 1999-02-09 Pfizer Prod Inc 2-aminopiridinas con sustituyentes alcoxi ramificados

Also Published As

Publication number Publication date
WO2001009307A2 (fr) 2001-02-08
WO2001009307A3 (fr) 2001-08-23
AU6174600A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
Johnson et al. Role of the peroxisome proliferator‐activated receptor in cytochrome P450 4A gene regulation
Lambe et al. A human peroxisome‐proliferator‐activated receptor‐γ is activated by inducers of adipogenesis, including thiazolidinedione drugs
Luo et al. Transcriptional inhibition by Stat5: differential activities at growth-related versus differentiation-specific promoters
EP0743520A2 (fr) Utilisations nouvelles des structures de GAL4-récepteur
US20080032961A1 (en) Therapy employing LXRalpha modolators
Sheu et al. Measurement of intracellular calcium using bioluminescent aequorin expressed in human cells
AU2952695A (en) Mammalian peroxisome proliferator-activated receptors and uses thereof
US6203982B1 (en) Method for screening compounds regulating the expression of human-inducible nitric oxide synthase
WO1992016658A1 (fr) Compositions a elements de reaction et dosages les incorporant
AU688282B2 (en) Stably-transformed mammalian cells expressing a regulated, inflammatory cyclooxygenase
EP1780278A2 (fr) Nouveaux canaux calciques mammifères et sondes, lignées cellulaires et procédés correspondants
WO1997049832A2 (fr) Procede d'identification du cytochrome p450
WO2001009307A2 (fr) Recherche systematique de modulateurs de synthase d'oxyde nitrique
US6492137B1 (en) Response element compositions and assays employing same
US20030113810A1 (en) Novel assay
WO1993022331A9 (fr) Crabp-i et crabp-ii humaines
WO1993022331A1 (fr) Crabp-i et crabp-ii humaines
CA2486576A1 (fr) Regulateurs et modulateurs de canal sodium
WO1999005292A1 (fr) Methode de criblage de genes utilisant les recepteurs nucleaires
US5654137A (en) Human CRABP-I and CRABP-II
Wiederkehr et al. Widely used enhancer of eukaryotic expression vectors is strongly and differentially regulated in fibroblast, myoblast, and teratocarcinoma cell lines
CN114940717A (zh) 嵌合受体、32d瘦素敏感细胞株及其应用
JP5062821B2 (ja) Ｎｏｔｃｈシグナル伝達を高感度で検出するレポーターコンストラクト
EP1318194A1 (fr) Procede de criblage de substances hypoglycemiantes a l'aide du facteur inhibiteur stat 1
JP2001078782A (ja) ダイオキシンレセプター遺伝子およびその利用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020227

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040103